Oncology
We’re excited to announce that the 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available! If you’re subscribed, you can now access the latest insights and data to enhance your market access strategies here: MORSE Reports Portal Not a subscriber yet? Don’t miss out—subscribe now to stay informed and take advantage of this valuable resource! MORSE Subscriptions
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic, which highlights key metrics from Q1 2024 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2023 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. …
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q4 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please…
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q3 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please…
For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report. Embed this infographic (copy and paste code) on your website with attribution: <p><a href="https://morseconsulting.ca/morse-consulting-releases-its-pcpa-quarterly-update-q2-2023"><img…
For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report. Embed this infographic (copy and paste code) on your website with attribution: <p><a href="https://morseconsulting.ca/morse-consulting-releases-its-pcpa-quarterly-update-q4-2022"><img…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size…
Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. Last quarter, Keytruda initiated and completed pCPA negotiations 2022-02-11. This was not captured in our previous update, but has since been accounted for in our dataset and the infographic below. For a more in-depth look at market access trends and…
MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. We extend our gratitude to those who provided feedback in anticipation for the transition to a quarterly update. We are pleased to release our first Quarterly pCPA Update Infographic. This resource is aimed at helping market access…
MORSE Consulting is pleased to release our Fifth Annual pCPA Year in Review Infographic – 2021 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2021. This infographic compares year-over-year metrics including: pCPA activity summary; addresses backlog of files under consideration; average time to complete a negotiation; and files adjudicated by the pCPA by type. MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT)…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2021 Trends and Insights UPDATE & REQUEST FOR PARTICIPATION IN A SURVEY MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. By analyzing quarterly vs. monthly data we expect to be able to identify important trends and provide useful insights…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2021 Trends and Insights November 2021 Highlights: 3 products completed CADTH review 15 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Key Take-Aways: The number of files under consideration was reduced substantially from 31 in October to 22 as of November 30th, driven by relatively few CADTH…
pan-Canadian Pharmaceutical Alliance (pCPA): October 2021 Trends and Insights October 2021 Highlights: 3 products completed CADTH review 6 products initiated pCPA negotiations 8 negotiations were completed with an LOI 0 negotiation were closed without an LOI 0 file were closed without negotiation Key Take-Aways: The volume of files under consideration has decreased steadily over the past three months from 37 in August to 31 as of October 31st.…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2021 Trends and Insights September 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 7 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation Key Take-Aways: The number of files under consideration at pCPA decreased slightly to 34 from last month’s high, while the average days under consideration had a…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Oncology - Info and details on - MORSE Consulting Inc.
